Merck’s Remigromig Meets Primary Endpoint in Diabetic Macular Edema Study

Key Facts

1Merck's remigromig met the primary endpoint in a clinical study for diabetic macular edema (DME).

2The drug demonstrated non-inferiority to ranibizumab, while further safety analyses are ongoing.

Merck & Co., Inc. announced that its investigational drug remigromig met the primary endpoint in a clinical study for diabetic macular edema (DME). Zacks reported that the drug demonstrated non-inferiority to ranibizumab, the standard treatment for vision loss caused by diabetes.

MRK shares closed at $148.01 on September 24, 2026, after reaching a day high of $151.46. Further safety analyses are currently ongoing as the company evaluates the drug's potential as a new treatment option within its biotechnology and healthcare portfolio.